Cover Image
市場調查報告書

子宮頸癌:開發平台分析

Cervical Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232853
出版日期 內容資訊 英文 472 Pages
訂單完成後即時交付
價格
Back to Top
子宮頸癌:開發平台分析 Cervical Cancer - Pipeline Review, H2 2016
出版日期: 2016年11月23日 內容資訊: 英文 472 Pages
簡介

子宮頸癌常是人類乳突病毒引發的,初期幾手沒有自覺症狀。症狀有不正常出血、性交或停經後、月經期以外出血等,治療方法有外科手術、放射治療,化療等聯合治療。

本報告提供子宮頸癌的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

子宮頸癌概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/實驗室

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • 3SBio Inc.
  • Admedus Ltd
  • Advaxis, Inc.
  • Advenchen Laboratories, LLC
  • AnGes MG, Inc.
  • Antigen Express, Inc.
  • Arbor Vita Corporation
  • ArQule, Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • Azaya Therapeutics, Inc.
  • Blirt S.A.
  • Bristol-Myers Squibb Company
  • Cancer Research Technology Limited
  • Cellceutix Corporation
  • Chong Kun Dang Pharmaceutical Corp.
  • Coherus BioSciences, Inc.
  • Critical Outcome Technologies Inc.
  • CZ BioMed Corp
  • DelMar Pharmaceuticals, Inc.
  • Dr. Reddy's Laboratories Limited
  • EirGenix Inc.
  • Eisai
  • Eureka Therapeutics, Inc
  • EyeGene, Inc. 63
  • F. Hoffmann-La Roche Ltd.
  • Formune S.L.
  • Genexine, Inc.
  • Genmab A/S
  • Genor BioPharma Co., Ltd.
  • Genticel S.A.
  • GlaxoSmithKline Plc
  • Immunovaccine, Inc.
  • ISA Pharmaceuticals B.V.
  • Johnson & Johnson
  • Karyopharm Therapeutics, Inc.
  • Kite Pharma, Inc.
  • LondonPharma Ltd
  • Mabion SA . 77
  • MedImmune, LLC
  • MEI Pharma, Inc.
  • Mundipharma International Ltd
  • Mycenax Biotech Inc.
  • Nanotherapeutics, Inc.
  • Nektar Therapeutics
  • Novartis AG
  • Oncobiologics, Inc.
  • 小野藥品工業 .
  • Oryx GmbH & Co. KG
  • 大塚集團
  • PDS Biotechnology Corporation
  • Pfizer Inc.
  • Psicofarma S.A. de C.V.
  • Rexahn Pharmaceuticals, Inc.
  • Samyang Holdings Corporation
  • Sanofi
  • Savoy Pharmaceuticals, Inc.
  • Seattle Genetics, Inc.
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Shantha Biotechnics Limited
  • Sirnaomics, Inc.
  • Sun Pharma Advanced Research Company Ltd.
  • 大鵬藥品工業
  • Theravectys SA
  • Tomegavax, Inc.
  • UbiVac, LLC
  • Vaccibody AS
  • VLPbio
  • Zeria Pharmaceutical Co., Ltd.
  • Zydus Cadila Healthcare Limited

治療藥的評估

  • 單獨療法的產品
  • 聯合治療的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發中產品的最新趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 注目資訊和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8700IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Pipeline Review, H2 2016, provides an overview of the Cervical Cancer (Oncology) pipeline landscape.

Cervical cancer occurs when abnormal cells on the cervix grow out of control. Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Abnormal cervical cell changes rarely cause symptoms. Symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding and spotting between periods, and having longer or heavier (menstrual) periods than usual. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 20, 29, 1, 39, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 1, 9 and 5 molecules, respectively.Cervical Cancer.

Cervical Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cervical Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Cervical Cancer - Overview
    • Pipeline Products for Cervical Cancer - Comparative Analysis
  • Cervical Cancer - Therapeutics under Development by Companies
  • Cervical Cancer - Therapeutics under Investigation by Universities/Institutes
  • Cervical Cancer - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Cervical Cancer - Products under Development by Companies
  • Cervical Cancer - Products under Investigation by Universities/Institutes
  • Cervical Cancer - Companies Involved in Therapeutics Development
    • Abion Inc
    • Admedus Ltd
    • Advaxis Inc
    • Advenchen Laboratories LLC
    • Antigen Express Inc
    • Arbor Vita Corp
    • ArQule Inc
    • AstraZeneca Plc
    • AVEO Pharmaceuticals Inc
    • Azaya Therapeutics Inc
    • Bioleaders Corporation
    • Biomics Biotechnologies Co Ltd
    • Blirt SA
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Cancer Research Technology Ltd
    • Cell Medica Ltd
    • Cellceutix Corp
    • Coherus BioSciences Inc
    • Critical Outcome Technologies Inc
    • CZ BioMed Corp
    • DelMar Pharmaceuticals, Inc.
    • Dr. Reddy's Laboratories Ltd
    • EirGenix Inc.
    • Eisai Co Ltd
    • Etubics Corp
    • Eureka Therapeutics Inc
    • EyeGene Inc
    • F. Hoffmann-La Roche Ltd
    • Formune SL
    • GamaMabs Pharma SA
    • Gene Techno Science Co Ltd
    • Genexine Inc
    • Genmab A/S
    • Genor BioPharma Co Ltd
    • Genticel S.A.
    • GlaxoSmithKline Plc
    • Immune Therapeutics, Inc.
    • Immunovaccine Inc
    • INSYS Therapeutics Inc
    • ISA Pharmaceuticals BV
    • Johnson & Johnson
    • Karyopharm Therapeutics Inc
    • Kite Pharma Inc
    • LondonPharma Ltd
    • Mabion SA
    • Merck & Co Inc
    • Mycenax Biotech Inc
    • Nanotherapeutics Inc
    • Nektar Therapeutics
    • Oncobiologics Inc
    • Ono Pharmaceutical Co Ltd
    • Oryx GmbH & Co KG
    • PDS Biotechnology Corp
    • Pfizer Inc
    • Psicofarma SA de CV
    • Rexahn Pharmaceuticals Inc
    • Richter Gedeon Nyrt
    • Samyang Holdings Corp
    • Sanofi
    • Savoy Pharmaceuticals, Inc.
    • Seattle Genetics Inc
    • Selecta Biosciences Inc
    • Shantha Biotechnics Ltd
    • Sirnaomics Inc
    • Sun Pharma Advanced Research Company Ltd
    • Taiho Pharmaceutical Co Ltd
    • Tessa Therapeutics Pte Ltd
    • Theravectys SA
    • THEVAX Genetics Vaccine USA Inc
    • Tomegavax Inc
    • UbiVac LLC
    • VLPbio
    • Zeria Pharmaceutical Co Ltd
    • Zydus Cadila Healthcare Ltd
  • Cervical Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (hydralazine + valproate magnesium) - Drug Profile
    • ABN-301 - Drug Profile
    • AEH-10p - Drug Profile
    • AL-3818 - Drug Profile
    • Ancer - Drug Profile
    • Antisense RNAi Oligonucleotide for Cervical Cancer - Drug Profile
    • Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile
    • ARQ-092 - Drug Profile
    • artemether - Drug Profile
    • atezolizumab - Drug Profile
    • AV-203 - Drug Profile
    • AVC-7 - Drug Profile
    • axalimogene filolisbac - Drug Profile
    • AZD-5363 - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • BLR-111 - Drug Profile
    • BLSILSB-710c - Drug Profile
    • BMS-986016 - Drug Profile
    • BVAC-C - Drug Profile
    • Cellular Immunotherapy for HPV Associated Cancers - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer - Drug Profile
    • Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer - Drug Profile
    • CerviVax - Drug Profile
    • Cervlysis - Drug Profile
    • CIGB-300 - Drug Profile
    • CMD-004 - Drug Profile
    • COTI-2 - Drug Profile
    • crocetin - Drug Profile
    • dianhydrogalactitol - Drug Profile
    • docetaxel - Drug Profile
    • DPXE-7 - Drug Profile
    • E-7046 - Drug Profile
    • EDA-HPVE7 - Drug Profile
    • EDOB-278 - Drug Profile
    • EF-022 - Drug Profile
    • EG-HPV - Drug Profile
    • Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile
    • ET-1502 - Drug Profile
    • ETBX-041 - Drug Profile
    • etirinotecan pegol - Drug Profile
    • GM-102 - Drug Profile
    • GSK-2256098 - Drug Profile
    • GSK-2849330 - Drug Profile
    • GTL-001 - Drug Profile
    • GTL-002 - Drug Profile
    • GX-I7 - Drug Profile
    • HPViNT - Drug Profile
    • human papillomavirus vaccine - Drug Profile
    • human papillomavirus vaccine - Drug Profile
    • human papillomavirus vaccine - Drug Profile
    • human papillomavirus vaccine - Drug Profile
    • human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar - Drug Profile
    • ISA-101 - Drug Profile
    • JNJ-61610588 - Drug Profile
    • Kevetrin - Drug Profile
    • KITE-439 - Drug Profile
    • LN-145 - Drug Profile
    • Lovaxin S - Drug Profile
    • Monoclonal Antibody Conjugate to Target CD40 for Cervical, Head And Neck Cancer - Drug Profile
    • naltrexone hydrochloride - Drug Profile
    • nimotuzumab - Drug Profile
    • nintedanib - Drug Profile
    • NIT-02 - Drug Profile
    • nivolumab - Drug Profile
    • NP-001 - Drug Profile
    • NTO-1151 - Drug Profile
    • Oncoprev - Drug Profile
    • OTAC-DCtag - Drug Profile
    • paclitaxel - Drug Profile
    • paclitaxel - Drug Profile
    • paclitaxel albumin free - Drug Profile
    • PDS-0101 - Drug Profile
    • pembrolizumab - Drug Profile
    • PF-04518600 - Drug Profile
    • phosphoethanolamine - Drug Profile
    • RA-190 - Drug Profile
    • Recombinant Protein to Inhibit NFKB for Cervical Cancer and Breast Cancer - Drug Profile
    • RG-7876 - Drug Profile
    • RX-3117 - Drug Profile
    • S-009131 - Drug Profile
    • SAR-408701 - Drug Profile
    • SEL-701 - Drug Profile
    • selinexor - Drug Profile
    • SGN-LIV1A - Drug Profile
    • sirolimus albumin-bound - Drug Profile
    • Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology - Drug Profile
    • STP-900 - Drug Profile
    • Subunit Vaccine for HPV Associated Cervical Cancer - Drug Profile
    • Synthetic Peptides to Inhibit Bcl-x and MCL-1 for Oncology - Drug Profile
    • TA-CIN - Drug Profile
    • TAS-114 - Drug Profile
    • Tenacinol - Drug Profile
    • tisotumab vedotin - Drug Profile
    • TT-12 - Drug Profile
    • TVGV-1 - Drug Profile
    • utomilumab - Drug Profile
    • Vaccine for HPV Associated Cancers - Drug Profile
    • Vaccine for HPV Associated Cervical Cancer - Drug Profile
    • Vaccine for HPV Associated Cervical Cancer - Drug Profile
    • Vaccine for HPV Associated Cervical Cancer - Drug Profile
    • Vaccine for Human papillomavirus Associated Cervical Cancer - Drug Profile
    • Vaccine to Target HIG2, VEGFR-1 and VEGFR-2 for Ovarian Cancer and Cervical Cancer - Drug Profile
    • Vaccine to Target HPV E7 Protein for Cervical Cancer - Drug Profile
    • Vaccine to Target HPV Minor Capsid Protein L2 for Cervical Cancer - Drug Profile
    • Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile
    • Vicoryx - Drug Profile
    • Vvax-001 - Drug Profile
  • Cervical Cancer - Dormant Projects
  • Cervical Cancer - Discontinued Products
  • Cervical Cancer - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cervical Cancer, H2 2016
  • Number of Products under Development for Cervical Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Cervical Cancer - Pipeline by Abion Inc, H2 2016
  • Cervical Cancer - Pipeline by Admedus Ltd, H2 2016
  • Cervical Cancer - Pipeline by Advaxis Inc, H2 2016
  • Cervical Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016
  • Cervical Cancer - Pipeline by Antigen Express Inc, H2 2016
  • Cervical Cancer - Pipeline by Arbor Vita Corp, H2 2016
  • Cervical Cancer - Pipeline by ArQule Inc, H2 2016
  • Cervical Cancer - Pipeline by AstraZeneca Plc, H2 2016
  • Cervical Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016
  • Cervical Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016
  • Cervical Cancer - Pipeline by Bioleaders Corporation, H2 2016
  • Cervical Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2016
  • Cervical Cancer - Pipeline by Blirt SA, H2 2016
  • Cervical Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Cervical Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Cervical Cancer - Pipeline by Cancer Research Technology Ltd, H2 2016
  • Cervical Cancer - Pipeline by Cell Medica Ltd, H2 2016
  • Cervical Cancer - Pipeline by Cellceutix Corp, H2 2016
  • Cervical Cancer - Pipeline by Coherus BioSciences Inc, H2 2016
  • Cervical Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016
  • Cervical Cancer - Pipeline by CZ BioMed Corp, H2 2016
  • Cervical Cancer - Pipeline by DelMar Pharmaceuticals, Inc., H2 2016
  • Cervical Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016
  • Cervical Cancer - Pipeline by EirGenix Inc., H2 2016
  • Cervical Cancer - Pipeline by Eisai Co Ltd, H2 2016
  • Cervical Cancer - Pipeline by Etubics Corp, H2 2016
  • Cervical Cancer - Pipeline by Eureka Therapeutics Inc, H2 2016
  • Cervical Cancer - Pipeline by EyeGene Inc, H2 2016
  • Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Cervical Cancer - Pipeline by Formune SL, H2 2016
  • Cervical Cancer - Pipeline by GamaMabs Pharma SA, H2 2016
  • Cervical Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2016
  • Cervical Cancer - Pipeline by Genexine Inc, H2 2016
  • Cervical Cancer - Pipeline by Genmab A/S, H2 2016
  • Cervical Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016
  • Cervical Cancer - Pipeline by Genticel S.A., H2 2016
  • Cervical Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Cervical Cancer - Pipeline by Immune Therapeutics, Inc., H2 2016
  • Cervical Cancer - Pipeline by Immunovaccine Inc, H2 2016
  • Cervical Cancer - Pipeline by INSYS Therapeutics Inc, H2 2016
  • Cervical Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2016
  • Cervical Cancer - Pipeline by Johnson & Johnson, H2 2016
  • Cervical Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016
  • Cervical Cancer - Pipeline by Kite Pharma Inc, H2 2016
  • Cervical Cancer - Pipeline by LondonPharma Ltd, H2 2016
  • Cervical Cancer - Pipeline by Mabion SA, H2 2016
  • Cervical Cancer - Pipeline by Merck & Co Inc, H2 2016
  • Cervical Cancer - Pipeline by Mycenax Biotech Inc, H2 2016
  • Cervical Cancer - Pipeline by Nanotherapeutics Inc, H2 2016
  • Cervical Cancer - Pipeline by Nektar Therapeutics, H2 2016
  • Cervical Cancer - Pipeline by Oncobiologics Inc, H2 2016
  • Cervical Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
  • Cervical Cancer - Pipeline by Oryx GmbH & Co KG, H2 2016
  • Cervical Cancer - Pipeline by PDS Biotechnology Corp, H2 2016
  • Cervical Cancer - Pipeline by Pfizer Inc, H2 2016
  • Cervical Cancer - Pipeline by Psicofarma SA de CV, H2 2016
  • Cervical Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2016
  • Cervical Cancer - Pipeline by Richter Gedeon Nyrt, H2 2016
  • Cervical Cancer - Pipeline by Samyang Holdings Corp, H2 2016
  • Cervical Cancer - Pipeline by Sanofi, H2 2016
  • Cervical Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016
  • Cervical Cancer - Pipeline by Seattle Genetics Inc, H2 2016
  • Cervical Cancer - Pipeline by Selecta Biosciences Inc, H2 2016
  • Cervical Cancer - Pipeline by Shantha Biotechnics Ltd, H2 2016
  • Cervical Cancer - Pipeline by Sirnaomics Inc, H2 2016
  • Cervical Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016
  • Cervical Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016
  • Cervical Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016
  • Cervical Cancer - Pipeline by Theravectys SA, H2 2016
  • Cervical Cancer - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2016
  • Cervical Cancer - Pipeline by Tomegavax Inc, H2 2016
  • Cervical Cancer - Pipeline by UbiVac LLC, H2 2016
  • Cervical Cancer - Pipeline by VLPbio, H2 2016
  • Cervical Cancer - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2016
  • Cervical Cancer - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Cervical Cancer - Dormant Projects, H2 2016
  • Cervical Cancer - Dormant Projects (Contd..1), H2 2016
  • Cervical Cancer - Dormant Projects (Contd..2), H2 2016
  • Cervical Cancer - Dormant Projects (Contd..3), H2 2016
  • Cervical Cancer - Dormant Projects (Contd..4), H2 2016
  • Cervical Cancer - Dormant Projects (Contd..5), H2 2016
  • Cervical Cancer - Dormant Projects (Contd..6), H2 2016
  • Cervical Cancer - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Cervical Cancer, H2 2016
  • Number of Products under Development for Cervical Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top